AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31517555 — intervention group
Group type: EXPERIMENTAL
Intervention: Kaempferia parviflora extract (KPE) - 5 tablets daily (150 mg KPFORCE™/tablet) for 4 weeks
Number of subjects: 52
Study 31517555 — intervention group
Group type: COMPARATOR
Intervention: Placebo - 5 tablets daily for 4 weeks
Number of subjects: 52
Study 29851751 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancrelipase (48,000 lipase units per meal)
Number of subjects: 88
Study 29851751 — intervention group
Group type: COMPARATOR
Intervention: Nonpancrelipase (control group)
Number of subjects: 88
Study 29851751 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancrelipase
Number of subjects: 88
Study 27054302 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation intentions (if-then plans)
Number of subjects: 168
Study 27054302 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation intentions (when-then plans)
Number of subjects: 168
Study 27054302 — intervention group
Group type: COMPARATOR
Intervention: Control group (no plans formed)
Number of subjects: 168
Study 25265548 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative functional reappraisal
Number of subjects: 99
Study 25265548 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance
Number of subjects: 99
Study 25265548 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative dysfunctional reappraisal
Number of subjects: 99
Study 25265548 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 99
Study 22770916 — intervention group
Group type: EXPERIMENTAL
Intervention: NIPPV (4 cmH(2)O IPAP + 4 cmH(2)O PEEP)
Number of subjects: 30
Study 22770916 — intervention group
Group type: COMPARATOR
Intervention: Tidal Volume Breathing (TVB)
Number of subjects: 30
Study 19918712 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% Boswellic acid cream
Number of subjects: 15
Study 19918712 — intervention group
Group type: COMPARATOR
Intervention: Base cream without Boswellic acid
Number of subjects: 15
Study 17265548 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxibustion
Number of subjects: 39
Study 17265548 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 39
Study 17265548 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture plus moxibustion
Number of subjects: 39
Study 16000173 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal endoscopic adhesiolysis
Number of subjects: 83
Study 16000173 — intervention group
Group type: COMPARATOR
Intervention: Control group (endoscopy into the sacral level without adhesiolysis, followed by injection of local anesthetic and steroid)
Number of subjects: 83
Study 12140473 — intervention group
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT) using methyl 5‐aminolevulinate cream 160 mg/g, 3 hours application time, and red light (75 J/cm(2))
Number of subjects: 193
Study 12140473 — intervention group
Group type: COMPARATOR
Intervention: Cryotherapy with liquid nitrogen spray
Number of subjects: 193
Study 12140473 — intervention group
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT) using methyl 5‐aminolevulinate
Number of subjects: 193
Study 10211540 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic QOL measures
Number of subjects: 0
Study 10211540 — intervention group
Group type: EXPERIMENTAL
Intervention: Disease-specific QOL measures
Number of subjects: 0
Study 7675960 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine (2, 4, and 8 mg sl.)
Number of subjects: 13
Study 7675960 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone (15, 30, and 60 mg PO)
Number of subjects: 13
Study 7675960 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 2287640 — intervention group
Group type: EXPERIMENTAL
Intervention: Valproinat
Number of subjects: 0
Study 2287640 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepin
Number of subjects: 0
Study 2287640 — intervention group
Group type: EXPERIMENTAL
Intervention: Diphenylhydantoin
Number of subjects: 0
Study 2287640 — intervention group
Group type: EXPERIMENTAL
Intervention: Primidon
Number of subjects: 0
Study 88342 — intervention group
Group type: EXPERIMENTAL
Intervention: Late component of the contingent negative variation (CNV)
Number of subjects: 8
Study 88342 — intervention group
Group type: EXPERIMENTAL
Intervention: Early CNV
Number of subjects: 8
Study 31884826 — intervention group
Group type: EXPERIMENTAL
Intervention: multi-phase intervention aimed at increasing social gaze behaviors
Number of subjects: 5
Study 31884826 — intervention group
Group type: EXPERIMENTAL
Intervention: multi-phase intervention
Number of subjects: 5
Study 26785097 — intervention group
Group type: EXPERIMENTAL
Intervention: Storz DCI® video laryngoscopy
Number of subjects: 93
Study 26785097 — intervention group
Group type: COMPARATOR
Intervention: Direct laryngoscopy
Number of subjects: 93
Study 26785097 — intervention group
Group type: EXPERIMENTAL
Intervention: GlideScope Cobalt® video laryngoscopy
Number of subjects: 93
Study 25567367 — intervention group
Group type: EXPERIMENTAL
Intervention: ABT-639 (up to 170 mg single dose and up to 160 mg BID multiple doses)
Number of subjects: 0
Study 25567367 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 0
Study 24359267 — intervention group
Group type: EXPERIMENTAL
Intervention: Obesity
Number of subjects: 412
Study 24359267 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress
Number of subjects: 412
Study 24359267 — intervention group
Group type: EXPERIMENTAL
Intervention: General health, mental health, sleep quality, vitality
Number of subjects: 412
Study 21493315 — intervention group
Group type: EXPERIMENTAL
Intervention: Coblation tonsillectomy
Number of subjects: 61
Study 21493315 — intervention group
Group type: COMPARATOR
Intervention: Electrocautery tonsillectomy
Number of subjects: 61
Study 19660605 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 80 mg
Number of subjects: 228
Study 19660605 — intervention group
Group type: COMPARATOR
Intervention: Simvastatin 20 mg
Number of subjects: 228
Study 16933268 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulins (IVIG)
Number of subjects: 37
Study 16933268 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-D immunoglobulin (anti-D)
Number of subjects: 37
Study 16933268 — intervention group
Group type: COMPARATOR
Intervention: High-dose methyl prednisolone (HDMP)
Number of subjects: 37
Study 15270996 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast negative evaluations
Number of subjects: 346
Study 15270996 — intervention group
Group type: COMPARATOR
Intervention: Slow negative evaluations
Number of subjects: 346
Study 15270996 — intervention group
Group type: EXPERIMENTAL
Intervention: Task performance
Number of subjects: 346
Study 11270019 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil (1 microgram kg‐1 bolus followed by 0.1 microgram kg‐1 min‐1 infusion)
Number of subjects: 30
Study 11270019 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil (0.1 microgram kg‐1 bolus over 60 s followed by 0.01 microgram kg‐1 min‐1 infusion)
Number of subjects: 30
Study 9059867 — intervention group
Group type: EXPERIMENTAL
Intervention: p53 immunostaining
Number of subjects: 33
Study 9059867 — intervention group
Group type: EXPERIMENTAL
Intervention: DNA-ploidy analysis
Number of subjects: 33
Study 9059867 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined p53 and DNA analysis
Number of subjects: 33
Study 8454379 — intervention group
Group type: EXPERIMENTAL
Intervention: Flosequinan
Number of subjects: 135
Study 8454379 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 135
Study 3810050 — intervention group
Group type: EXPERIMENTAL
Intervention: Pivampicillin/pivmecillinam (PAPM) 450 mg and 900 mg every 12 h until catheter removal (max 1 week)
Number of subjects: 261
Study 3810050 — intervention group
Group type: EXPERIMENTAL
Intervention: Pivampicillin/pivmecillinam (PAPM)
Number of subjects: 261
Study 3810050 — intervention group
Group type: COMPARATOR
Intervention: Cefotaxime (CFT) 1 g daily parenterally
Number of subjects: 261
Study 3810050 — intervention group
Group type: COMPARATOR
Intervention: Cefotaxime (CFT)
Number of subjects: 261
Study 29893193 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric exercise
Number of subjects: 23
Study 29893193 — intervention group
Group type: COMPARATOR
Intervention: Foam rolling
Number of subjects: 23
Study 30376893 — intervention group
Group type: EXPERIMENTAL
Intervention: TXA dose A (15 mg/kg bolus dose over 20 min, followed by 2 mg/kg/hr infusion over 8 h)
Number of subjects: 0
Study 30376893 — intervention group
Group type: EXPERIMENTAL
Intervention: TXA dose B (30 mg/kg bolus dose over 20 min, followed by 4 mg/kg/hr infusion over 8 h)
Number of subjects: 0
Study 30376893 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30376893 — intervention group
Group type: EXPERIMENTAL
Intervention: TXA dose A
Number of subjects: 0
Study 30376893 — intervention group
Group type: EXPERIMENTAL
Intervention: TXA dose B
Number of subjects: 0
Study 26942364 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal swab test
Number of subjects: 140
Study 26942364 — intervention group
Group type: COMPARATOR
Intervention: Urethral Q-tip test
Number of subjects: 140
Study 24705965 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural
Number of subjects: 1785
Study 24705965 — intervention group
Group type: COMPARATOR
Intervention: No Epidural
Number of subjects: 1785
Study 23112824 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting during Ramadan
Number of subjects: 102
Study 20520555 — intervention group
Group type: COMPARATOR
Intervention: Lactated Ringer's solution
Number of subjects: 200
Study 20520555 — intervention group
Group type: EXPERIMENTAL
Intervention: Colloid infusions (HES and human albumin)
Number of subjects: 200
Study 20520555 — intervention group
Group type: EXPERIMENTAL
Intervention: Colloids (HES and human albumin)
Number of subjects: 200
Study 20520555 — intervention group
Group type: EXPERIMENTAL
Intervention: Human albumin
Number of subjects: 200
Study 20520555 — intervention group
Group type: EXPERIMENTAL
Intervention: Succinylated gelatin and HES
Number of subjects: 200
Study 20520555 — intervention group
Group type: COMPARATOR
Intervention: Colloids vs. lactated Ringer's solution
Number of subjects: 200
Study 17431368 — intervention group
Group type: EXPERIMENTAL
Intervention: Androgen ablation
Number of subjects: 0
Study 17431368 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant radiation
Number of subjects: 0
Study 17431368 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary radiation
Number of subjects: 0
Study 17431368 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose escalation utilizing intensity modulated external beam radiation therapy or brachytherapy
Number of subjects: 0
Study 16199414 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycopyrrolate 6 microg kg(‐1)
Number of subjects: 45
Study 16199414 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycopyrrolate 12 microg kg(‐1)
Number of subjects: 45
Study 16199414 — intervention group
Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 45
Study 12028119 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine 10 mg
Number of subjects: 29
Study 12028119 — intervention group
Group type: EXPERIMENTAL
Intervention: Ebastine 10 mg
Number of subjects: 29
Study 12028119 — intervention group
Group type: EXPERIMENTAL
Intervention: Loratadine 10 mg
Number of subjects: 29
Study 12028119 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 10365192 — intervention group
Group type: EXPERIMENTAL
Intervention: Pergolide mesylate (12 weeks)
Number of subjects: 28
Study 10365192 — intervention group
Group type: COMPARATOR
Intervention: Risperidone (n = 9)
Number of subjects: 28
Study 10365192 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 5)
Number of subjects: 28
Study 10365192 — intervention group
Group type: COMPARATOR
Intervention: Placebo (2 weeks) followed by double-blind placebo-controlled design (24 weeks)
Number of subjects: 28
Study 7740638 — intervention group
Group type: EXPERIMENTAL
Intervention: Stroke unit treatment using Bobath principles
Number of subjects: 65
Study 7740638 — intervention group
Group type: COMPARATOR
Intervention: General medical unit treatment
Number of subjects: 65
Study 7740638 — intervention group
Group type: EXPERIMENTAL
Intervention: Stroke unit treatment
Number of subjects: 65
Study 2161614 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet A: 227 g canned beans daily in a single dose
Number of subjects: 24
Study 2161614 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet B: 227 g canned beans daily in a divided dose
Number of subjects: 24
Study 2161614 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet C: 182 g canned beans daily in a divided dose
Number of subjects: 24
Study 7217721 — intervention group
Group type: EXPERIMENTAL
Intervention: Killed influenza virus vaccine (A/New Jersey/76)
Number of subjects: 25
Study 30681712 — intervention group
Group type: EXPERIMENTAL
Intervention: READI2 (patient self-assessment combined with nurse assessment)
Number of subjects: 144868
Study 30681712 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 144868
Study 30681712 — intervention group
Group type: EXPERIMENTAL
Intervention: READI protocols (including READI1 and READI3)
Number of subjects: 144868
Study 27979988 — intervention group
Group type: EXPERIMENTAL
Intervention: Histamine receptor antagonist
Number of subjects: 49
Study 27979988 — intervention group
Group type: COMPARATOR
Intervention: Control placebo
Number of subjects: 49
Study 27979988 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate treadmill exercise
Number of subjects: 49
Study 27979988 — intervention group
Group type: EXPERIMENTAL
Intervention: Histamine receptor blockade
Number of subjects: 49
Study 25833732 — intervention group
Group type: EXPERIMENTAL
Intervention: CORDIAL cognitive behavioral/cognitive rehabilitation (CB/CR) program
Number of subjects: 201
Study 25833732 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 201
Study 24162809 — intervention group
Group type: EXPERIMENTAL
Intervention: RT + PCV chemotherapy
Number of subjects: 32
Study 24162809 — intervention group
Group type: COMPARATOR
Intervention: RT
Number of subjects: 32
Study 24162809 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients' HRQOL
Number of subjects: 32
Study 24162809 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognition assessment
Number of subjects: 32
Study 24162809 — intervention group
Group type: EXPERIMENTAL
Intervention: Progression-free patients' HRQOL
Number of subjects: 32
Study 21134328 — intervention group
Group type: EXPERIMENTAL
Intervention: HPHchol diet (high-protein high-cholesterol); 590 mg cholesterol; 2 eggs per day; duration 12 weeks
Number of subjects: 65
Study 21134328 — intervention group
Group type: EXPERIMENTAL
Intervention: HPHchol diet
Number of subjects: 65
Study 21134328 — intervention group
Group type: COMPARATOR
Intervention: HPLchol diet (high-protein low-cholesterol); 213 mg cholesterol; replaced eggs with 100 g of lean animal protein; duration 12 weeks
Number of subjects: 65
Study 19303978 — intervention group
Group type: COMPARATOR
Intervention: Control (0.04 g/min glucose)
Number of subjects: 6
Study 19303978 — intervention group
Group type: EXPERIMENTAL
Intervention: High (0.8 g/min glucose)
Number of subjects: 6
Study 19303978 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-CHO diet without exercise
Number of subjects: 6
Study 19303978 — intervention group
Group type: EXPERIMENTAL
Intervention: High-CHO diet without exercise
Number of subjects: 6
Study 19402905 — intervention group
Group type: EXPERIMENTAL
Intervention: Loozit group weight management program (G)
Number of subjects: 168
Study 19402905 — intervention group
Group type: EXPERIMENTAL
Intervention: Loozit group weight management program plus additional therapeutic contact (G+ATC)
Number of subjects: 168
Study 16137403 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil (50 mg, adjusted to 25 mg or 100 mg according to efficacy and toxicity)
Number of subjects: 120
Study 16137403 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 12045491 — intervention group
Group type: EXPERIMENTAL
Intervention: TDF 75 mg
Number of subjects: 189
Study 12045491 — intervention group
Group type: EXPERIMENTAL
Intervention: TDF 150 mg
Number of subjects: 189
Study 12045491 — intervention group
Group type: EXPERIMENTAL
Intervention: TDF 300 mg
Number of subjects: 189
Study 12045491 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 189
Study 10080461 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalteparin (100 IU/kg before streptokinase and 120 IU/kg after 12 h)
Number of subjects: 101
Study 10080461 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalteparin (in patients with early reperfusion)
Number of subjects: 101
Study 10080461 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalteparin
Number of subjects: 101
Study 7590049 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic variceal sclerotherapy
Number of subjects: 90
Study 7590049 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic variceal ligation
Number of subjects: 90
Study 2252186 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal mask airway
Number of subjects: 48
Study 2252186 — intervention group
Group type: COMPARATOR
Intervention: Standard facemask
Number of subjects: 48
Study 7237926 — intervention group
Group type: COMPARATOR
Intervention: [14C]‐glycocholic acid (bolus injection or constant infusion)
Number of subjects: 21
Study 7237926 — intervention group
Group type: COMPARATOR
Intervention: [14C]cholic acid
Number of subjects: 21
Study 7237926 — intervention group
Group type: EXPERIMENTAL
Intervention: [14C]‐glycocholic acid
Number of subjects: 21
Study 7237926 — intervention group
Group type: EXPERIMENTAL
Intervention: Estimates of liver flow from [14C]glycocholic acid
Number of subjects: 21
Study 30309008 — intervention group
Group type: EXPERIMENTAL
Intervention: counseling + application
Number of subjects: 833
Study 30309008 — intervention group
Group type: COMPARATOR
Intervention: counseling
Number of subjects: 833
Study 27007580 — intervention group
Group type: EXPERIMENTAL
Intervention: Gestational weight gain restriction program
Number of subjects: 302
Study 27007580 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 302
Study 24866329 — intervention group
Group type: EXPERIMENTAL
Intervention: sitagliptin
Number of subjects: 29
Study 24866329 — intervention group
Group type: EXPERIMENTAL
Intervention: mitiglinide
Number of subjects: 29
Study 24866329 — intervention group
Group type: EXPERIMENTAL
Intervention: mitiglinide/voglibose combination
Number of subjects: 29
Study 22306193 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD1236 75 mg twice daily for 6 weeks
Number of subjects: 55
Study 22306193 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 20544348 — intervention group
Group type: EXPERIMENTAL
Intervention: OCC-walk (blood flow occlusion)
Number of subjects: 12
Study 18371094 — intervention group
Group type: EXPERIMENTAL
Intervention: Early loading (test, n=16)
Number of subjects: 24
Study 18371094 — intervention group
Group type: COMPARATOR
Intervention: Delayed loading (control, n=8)
Number of subjects: 24
Study 18371094 — intervention group
Group type: EXPERIMENTAL
Intervention: Technical complications
Number of subjects: 24
Study 18371094 — intervention group
Group type: EXPERIMENTAL
Intervention: Lingual gold onlay
Number of subjects: 24
Study 16550603 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin administered intravenously (IV, 100 mg/m2)
Number of subjects: 35
Study 16550603 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin administered intra-arterially (IA, 150 mg/m2)
Number of subjects: 35
Study 16550603 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher GG adduct levels (>median) in primary tumor
Number of subjects: 35
Study 12491212 — intervention group
Group type: EXPERIMENTAL
Intervention: Minocycline-ethylenediaminetetraacetate (M-EDTA) lock solution
Number of subjects: 14
Study 12491212 — intervention group
Group type: COMPARATOR
Intervention: Heparin flush (Control)
Number of subjects: 14
Study 10853165 — intervention group
Group type: EXPERIMENTAL
Intervention: Charnley prosthesis with an ogee flanged cup
Number of subjects: 372
Study 10853165 — intervention group
Group type: EXPERIMENTAL
Intervention: Spectron prosthesis with a metal backed cup
Number of subjects: 372
Study 10853165 — intervention group
Group type: EXPERIMENTAL
Intervention: All 410 hips (combined analysis)
Number of subjects: 372
Study 10853165 — intervention group
Group type: EXPERIMENTAL
Intervention: Expanded definition of failure including patient dissatisfaction
Number of subjects: 372
Study 10853165 — intervention group
Group type: COMPARATOR
Intervention: Charnley prosthesis (Swedish National Hip Registry)
Number of subjects: 372
Study 10853165 — intervention group
Group type: COMPARATOR
Intervention: Spectron prosthesis (Swedish National Hip Registry)
Number of subjects: 372
Study 8917004 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% lignocaine infiltration into the subserosal aspect of the cornual end of the fallopian tubes
Number of subjects: 59
Study 8917004 — intervention group
Group type: COMPARATOR
Intervention: Normal saline infiltration into the subserosal aspect of the cornual end of the fallopian tubes
Number of subjects: 59
Study 8917004 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% lignocaine infiltration
Number of subjects: 59
Study 1756285 — intervention group
Group type: EXPERIMENTAL
Intervention: Otilonium bromide (OB) 40 mg tid
Number of subjects: 72
Study 1756285 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 7017982 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine, 300 mg IV every 6 hours
Number of subjects: 300
Study 7017982 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 300
Study 7017982 — intervention group
Group type: EXPERIMENTAL
Intervention: Antacid titration to maintain gastric pH > 4.0
Number of subjects: 300
Study 31336262 — intervention group
Group type: EXPERIMENTAL
Intervention: High self-focused attention (focusing on a disliked part in a mirror placed 10 cm away)
Number of subjects: 51
Study 31336262 — intervention group
Group type: COMPARATOR
Intervention: Low self-focused attention (looking into a mirror placed 100 cm away)
Number of subjects: 51
Study 29457034 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral arm crank exercise test
Number of subjects: 16
Study 29457034 — intervention group
Group type: EXPERIMENTAL
Intervention: Leg cycle exercise test
Number of subjects: 16
Study 29457034 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy individuals)
Number of subjects: 16